Biosimilar medicationsnewer biologics that are highly similar to established biologic medications whose patent protections have expiredare just beginning to be introduced in the United States. Although they have been used elsewhere in the world for some time now, biosimilars are still novel in the United States, with great potential for confusion among clinicians and patients. This activity is intended to provide background and clarity on how to evaluate and use biosimilars; whether and how they differ from the originator biologics on which they are based; and why they should not be equated with generic versions of conventional small-molecule medications.
Ratings and Reviews
To review this course, please login.Login